MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
7.67
-1.23
-13.82%
After Hours: 7.89 +0.22 +2.87% 19:08 05/15 EDT
OPEN
8.80
PREV CLOSE
8.90
HIGH
9.09
LOW
7.50
VOLUME
998.05K
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
3.650
MARKET CAP
172.97M
P/E (TTM)
-0.5167
1D
5D
1M
3M
1Y
5Y
1D
Karyopharm Therapeutics (KPTI) Quarterly Loss Deepens Reinforcing Bearish Profitability Concerns
Simply Wall St · 19h ago
Leerink Partners Sticks to Its Hold Rating for Karyopharm Therapeutics (KPTI)
TipRanks · 1d ago
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanks · 1d ago
Karyopharm Earnings Call: Trial Wins, Cash Questions
TipRanks · 1d ago
Karyopharm outlines $130M-$150M 2026 revenue outlook as it prepares mid-2026 XPORT-EC-042 readout
Seeking Alpha · 2d ago
Karyopharm (KPTI) Q1 2026 Earnings Transcript
The Motley Fool · 2d ago
Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga · 2d ago
Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)
TipRanks · 2d ago
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.